Biomotion Sciences. Ordinary Shares SLXN 深 滬
交易中 09-25 10:15:15 美东时间
0.2499
-0.007
-2.76%
華盛通- 最 高0.2523
- 今 開0.24
- 成交量 43.68万股
- 最 低 0.238
- 昨 收 0.257
- 總市值 138.95万
- 52周最高 42.00
- 市盈率 靜 --
- 換手率 7.86%
- 52周最低 0.238
- 委 比 -96.41%
- 總股本 556.03万
- 歷史最高 6277.50
- 量 比 0.32
- 振 幅 5.56%
- 歷史最低 0.238
- 每 手 1
- 風險率 12.08%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Silexion Therapeutics Q2 EPS $(5.17) Misses $(2.12) Estimate
Silexion Therapeutics (NASDAQ:SLXN) reported quarterly losses of $(5.17) per share which missed the analyst consensus estimate of $(2.12) by 143.87 percent. This is a 88.03 percent increase over losses of $(43.20) per share from the same period last year.
08-14 21:02
Silexion Therapeutics Receives Approval From Germany's Federal Institute For Drugs And Medical Devices To Start Its Planned Phase 2/3 Clinical Study Of SIL204 In Participants With Locally Advanced Pancreatic Cancer
Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that it has received formal approval from Germany's Federal Institute for Drugs and Medical Devices (B...
06-23 20:41
Silexion Therapeutics Announces 1-For-10 Reverse Share Split Of Ordinary Shares, Effective May 28
Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-10 reverse
05-26 20:33
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 147.2% to ...
05-20 20:06
Silexion Therapeutics Q1 EPS $(0.85) Beats $(1.29) Estimate
Silexion Therapeutics (NASDAQ:SLXN) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate of $(1.29) by 34.11 percent. This is a 77.86 percent increase over losses of $(3.84) per share
05-16 06:58
Silexion Therapeutics Initiates Good Manufacturing Practice Clinical Batch Manufacturing Of SIL204 In Support Of Planned Upcoming Phase 2/3 Clinical Trial In LAPC
Silexion advances toward Phase 2/3 trial in KRAS-driven pancreatic cancer, as SIL204 begins GMP clinical manufacturing in collaboration with global leading manufacturing partner Catalent at its European center of
05-13 20:04
Silexion Therapeutics shares are trading lower. The company announced the submission of a Clinical Trial Application to Germany for its planned Phase 2/3 clinical trial of its lead, siRNA product candidate, SIL204.
Silexion Therapeutics shares are trading lower. The company announced the submi...
04-29 03:20
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock increased by 63.0% to $0...
04-25 01:05
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Psyence Biomedical (NASDAQ:PBM) shares increased by 63.4% to $9.59 dur...
04-17 05:05
Silexion Secures Regulatory Approval To Launch Phase 2/3 Trials Of SIL204 RNAi Therapy Targeting KRAS-Driven Pancreatic Cancer
Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated systemic treatment delivery approach targeting highly prevalent
03-24 20:38
